---
title: "InSilico Medicine’s UAE Team Advances AI-Designed Brain Cancer Drug to Preclinical Stage"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283909327.md"
description: "InSilico Medicine has announced that its UAE team has advanced ISM0387, an AI-designed brain cancer drug, to the preclinical stage. This candidate, a PRMT5 inhibitor, was developed in under 12 months and shows promise for treating glioblastoma. The achievement highlights the company's AI-driven drug discovery capabilities and its integration into Abu Dhabi's life sciences ecosystem, supported by local health and investment authorities. InSilico Medicine continues to expand its portfolio of AI-supported preclinical candidates, enhancing its competitive position in the industry."
datetime: "2026-04-24T00:13:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283909327.md)
  - [en](https://longbridge.com/en/news/283909327.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283909327.md)
---

# InSilico Medicine’s UAE Team Advances AI-Designed Brain Cancer Drug to Preclinical Stage

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

InSilico Medicine Cayman TopCo ( (HK:3696) ) has issued an announcement.

InSilico Medicine has announced that its UAE research team has nominated ISM0387, an AI-designed MTA-cooperative PRMT5 inhibitor, as a preclinical candidate, marking a rapid discovery cycle from molecular design to lead optimization in under 12 months. The molecule, which shows improved activity, selectivity and brain penetration, is positioned as a potential new treatment for glioblastoma and underscores the growing role of regional R&D hubs in the company’s pipeline.

The selection of ISM0387 as the group’s 30th AI-supported preclinical candidate highlights the scale and maturity of InSilico Medicine’s AI-enabled portfolio and may strengthen its competitive standing in AI-first drug discovery. The achievement, backed publicly by UAE health and investment authorities, reinforces the company’s strategic integration into Abu Dhabi’s emerging life sciences ecosystem and signals continued support for its regional and global development efforts.

**More about InSilico Medicine Cayman TopCo**

InSilico Medicine Cayman TopCo is an AI-driven drug discovery company that uses its proprietary Pharma.AI platform to design and optimize novel therapeutic candidates. The group focuses on accelerating early-stage discovery in oncology and other disease areas, with a growing portfolio of AI-supported preclinical drug programs targeting global markets.

**Average Trading Volume:** 3,091,101

**Current Market Cap:** HK$39.12B

For an in-depth examination of 3696 stock, go to TipRanks’ Overview page.

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [09:00 ETGenerative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE](https://longbridge.com/en/news/284007341.md)
- [InSilico Medicine Wins China IND Nod for AI-Discovered IPF Drug Rentosertib](https://longbridge.com/en/news/284467539.md)
- [Citadel CEO Ken Griffin was a prominent AI skeptic. Now he says, 'AI is real.'](https://longbridge.com/en/news/286683665.md)
- [Cathie Wood Snatches Up $46.4 Million of the Hottest AI IPO of the Year. Here’s Why.](https://longbridge.com/en/news/286795261.md)
- [AI investment 'advice' is 50% more likely to pump you up - and trip you into costly blunders](https://longbridge.com/en/news/286651216.md)